ArticleLa Radiologia medica2026
Added value of intravoxel incoherent motion histogram analysis in differentiating HER2-zero, HER2-low, and HER2-positive breast cancer.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeAccurate differentiation of human epidermal growth factor receptor 2 (HER2)-zero, HER2-low, and HER2-positive breast cancer (BC) is crucial for guiding therapeutic decisions, particularly with the development of novel HER2-targeted treatments. This study aimed to evaluate whether intravoxel incoherent motion (IVIM) imaging histogram parameters could provide additional diagnostic value in distinguishing among these HER2 expression subtypes beyond conventional BI-RADS assessments. MATERIALS AND
methodsThis retrospective single-center study included 181 breast cancer patients (30 HER2-zero, 107 HER2-low, and 44 HER2-positive). All patients underwent preoperative breast MRI on a 3.0-T scanner, including conventional sequences (T1-weighted, T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging) and intravoxel incoherent motion (IVIM) imaging. Histogram features derived from IVIM parameters-true diffusion coefficient (D), pseudo-diffusion coefficient (D*), and perfusion fraction (f)-were extracted and compared across the HER2 subgroups. Two diagnostic models were constructed: a conventional model based on BI-RADS features and a combined model incorporating both BI-RADS and IVIM histogram features. Statistical analyses included univariate logistic regression, Akaike information criterion (AIC), area under the receiver operating characteristic curve (AUC), integrated discrimination improvement (IDI), net reclassification index (NRI), and DeLong test.
resultsConventional BI-RADS features alone could not distinguish between HER2-zero and HER2-low tumors. Although D_Entropy demonstrated modest discrimination (AUC = 0.569), this comparison was analyzed descriptively without constructing predictive models. Consequently, conventional and combined models were not constructed for this comparison. For HER2-low versus HER2-positive differentiation, the combined model (including D_Skewness and tumor size) achieved significantly higher performance (AUC = 0.727) than the conventional model (AUC = 0.587). Similarly, for HER2-zero versus HER2-positive, the combined model (D_Skewness, tumor size, and axillary lymph node [ALN] status) outperformed the conventional model (tumor size and ALN status), with AUCs of 0.730 versus 0.700. Improvements in diagnostic performance with the combined model were statistically confirmed by the DeLong test, NRI, and IDI metrics in the HER2-low versus HER2-positive and HER2-zero versus HER2-positive comparisons.
conclusionsIVIM histogram parameters, particularly D_Skewness and D_Entropy, may enhance the ability to differentiate HER2 expression subtypes in breast cancer when integrated with conventional BI-RADS features. The combined model improves diagnostic performance, supporting its potential utility in refining HER2 status evaluation and optimizing personalized treatment strategies.
Indexed as
Identifiers
42126725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.